Key facts
- It has raised $41.6M across 3 recorded rounds; the latest was Early Stage VC ($12.0M) in Mar 2024.
- Notable investors include TEDCO, Vanedge Capital, Allison Kumar, Andras Forgacs, Andrew Sharpless — 18 tracked in total.
- RoosterBio has filed 6 Form Ds with the SEC since 2014, most recently Jul 2024 ($12.0M sold to 8 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 18 names
- ·Watchlist + deal alerts for RoosterBio
Funding rounds
3 roundsAbout RoosterBio
Developer of cell-based systems designed for the development and scale-up of regenerative medicine applications. The company system includes standardized, high-yield human mesenchymal stromal cell and extracellular vesicle production systems integrated with scalable 2D and 3D bioprocessing tools, optimized media, cGMP-grade components, and analytical services, enabling therapeutic developers in cell therapy, gene therapy, and tissue engineering to streamline product development, reduce costs, and accelerate clinical and commercial translation.
- Sector
- Healthcare
- HQ
- Frederick, MD, United States
- Founded
- 2013
- Employees
- 57
- Website
- roosterbio.com/
- Ownership
- Privately Held (backing)
RoosterBio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in RoosterBio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on RoosterBio in its N-PORT filings yet. We sweep new filings monthly.